Evidence map›Paper›PMID 38733599›Full record

ArticleACS synthetic biology2024

Molecular Engineering of Functional SiRNA Agents.

Neelu Batra, Mei-Juan Tu, Ai-Ming Yu

Abstract read
In one paragraph

Article in ACS synthetic biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Efficiency and safety of five different agents forFrontiers in molecular biosciences · 2026
    Article
  4. Article
  5. In Vivo Fermentation Production of RNA Interference Agents.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Neelu BatraDepartment of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, California 95817, United States.
Mei-Juan TuDepartment of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, California 95817, United States.
Ai-Ming YuDepartment of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, California 95817, United States.ORCID 0000-0003-1441-4012

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Barbara L. Shacklett · 2002 to 2026
$84.9M
Novel bioengineered microRNA therapeutics for lung cancerR01CA225958 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Aiming Yu · 2019 to 2026
$3.7M
Novel biologic RNA molecules to modulate HCC metabolismR01CA291771 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Aiming Yu · 2024 to 2026
$2.4M
Supplement: Recombinant microRNAs in xenobiotic metabolism and dispositionR35GM140835 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI YU, AIMING · 2021 to 2025
$2.0M
Recombinant microRNAs in xenobiotic and nutrient dispositionR01CA253230 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Meijuan Tu · 2021 to 2026
$1.7M
NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA225958NCI NIH HHS R01 CA253230NCI NIH HHS R01 CA291771NIGMS NIH HHS R35 GM140835
6 · The paper itself

Abstract

Synthetic biology constitutes a scientific domain focused on intentional redesign of organisms to confer novel functionalities or create new products through strategic engineering of their genetic makeup. Leveraging the inherent capabilities of nature, one may address challenges across diverse sectors including medicine. Inspired by this concept, we have developed an innovative bioengineering platform, enabling high-yield and large-scale production of biological small interfering RNA (BioRNA/siRNA) agents via bacterial fermentation. Herein, we show that with the use of a new tRNA fused pre-miRNA carrier, we can produce various forms of BioRNA/siRNA agents within living host cells. We report a high-level overexpression of nine target BioRNA/siRNA molecules at 100% success rate, yielding 3-10 mg of BioRNA/siRNA per 0.25 L of bacterial culture with high purity (>98%) and low endotoxin (<5 EU/μg RNA). Furthermore, we demonstrate that three representative BioRNA/siRNAs against GFP, BCL2, and PD-L1 are biologically active and can specifically and efficiently silence their respective targets with the potential to effectively produce downstream antiproliferation effects by PD-L1-siRNA. With these promising results, we aim to advance the field of synthetic biology by offering a novel platform to bioengineer functional siRNA agents for research and drug development.

Indexed as

RNA, Small InterferingEscherichia coliGenetic EngineeringGreen Fluorescent ProteinsHumansMicroRNAsProto-Oncogene Proteins c-bcl-2RNA, TransferSynthetic BiologyGreen Fluorescent ProteinsMicroRNAsProto-Oncogene Proteins c-bcl-2RNA, Small InterferingRNA, TransferRNA engineeringRNA interferencesmall interfering RNAtherapy

Identifiers

PMID38733599
PMCPMC11197084

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.